Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Active, not recruiting · NCT02453620 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | breast adenocarcinoma, invasive breast carcinoma | Active, not recruiting | Phase 1 | 2026-09-15 | NCT02453620 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | United States | 263 |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | United States | 238 |
| Smilow Cancer Center/Yale-New Haven Hospital | New Haven | United States | 91 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |
| Yale University | New Haven | United States | 352 |